FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376598514> ?p ?o ?g. }

• W4376598514 endingPage "1009" @default.
• W4376598514 startingPage "997" @default.
• W4376598514 abstract "Posaconazole (PSZ) is a triazole antifungal for the management of invasive fungal disease (IFD) in adults and children. Although PSZ is available as an intravenous (IV) solution, oral suspension (OS) and delayed-release tablets (DRTs), OS is the preferred formulation for pediatric use because of potential safety concerns associated with an excipient in the IV formulation and difficulty in swallowing intact tablets by children. However, poor biopharmaceutical characteristics of the OS formulation leads to an unpredictable dose-exposure profile of PSZ in children, potentially risking therapeutic failure. The goal of this study was to characterize the population pharmacokinetics (PK) of PSZ in immunocompromised children and assess therapeutic target attainment.Serum concentrations of PSZ were collected retrospectively from records of hospitalized patients. A population PK analysis was performed in a nonlinear mixed-effects modeling framework with NONMEM (v7.4). The PK parameters were scaled to body weight, then potential covariate effects were assessed. The final PK model was used to evaluate recommended dosing schemes through simulation of target attainment (as a percentage of the population having steady-state trough concentrations above the recommended target) using Simulx (v2021R1).Repeated measurement data of 202 serum concentrations of total PSZ were acquired from 47 immunocompromised patients between 1 and 21 years of age receiving PSZ either intravenously or orally, or both. A one-compartment PK model with first-order absorption and linear elimination best fit the data. The estimated absolute bioavailability (95% confidence interval) for suspension (Fs) was 16% (8-27%), which was significantly lower than the reported tablet bioavailability (Ft) [67%]. Fs was reduced by 62% and 75% upon concomitant administration with pantoprazole (PAN) and omeprazole (OME), respectively. Famotidine resulted in a reduction of Fs by only 22%. Both fixed dosing and weight-based adaptive dosing provided adequate target attainment when PAN or OME were not coadministered with the suspension.The results of this study revealed that both fixed and weight-based adaptive dosing schemes can be appropriate for target attainment across all PSZ formulations, including suspension. Additionally, covariate analysis suggests that concomitant proton pump inhibitors should be contraindicated during PSZ suspension dosing." @default.
• W4376598514 created "2023-05-17" @default.
• W4376598514 creator A5017147502 @default.
• W4376598514 creator A5024637021 @default.
• W4376598514 creator A5062283881 @default.
• W4376598514 creator A5069728691 @default.
• W4376598514 creator A5075015951 @default.
• W4376598514 creator A5076058449 @default.
• W4376598514 date "2023-05-14" @default.
• W4376598514 modified "2023-10-08" @default.
• W4376598514 title "Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease" @default.
• W4376598514 cites W1626439759 @default.
• W4376598514 cites W169280909 @default.
• W4376598514 cites W1866114906 @default.
• W4376598514 cites W1989345554 @default.
• W4376598514 cites W1999521622 @default.
• W4376598514 cites W2000502211 @default.
• W4376598514 cites W2003024054 @default.
• W4376598514 cites W2016290575 @default.
• W4376598514 cites W2017397613 @default.
• W4376598514 cites W2020365240 @default.
• W4376598514 cites W2042553471 @default.
• W4376598514 cites W2044502735 @default.
• W4376598514 cites W2056880246 @default.
• W4376598514 cites W2067101775 @default.
• W4376598514 cites W2072794245 @default.
• W4376598514 cites W2087640030 @default.
• W4376598514 cites W2101785863 @default.
• W4376598514 cites W2114061161 @default.
• W4376598514 cites W2117813373 @default.
• W4376598514 cites W2122855609 @default.
• W4376598514 cites W2126064588 @default.
• W4376598514 cites W2127167028 @default.
• W4376598514 cites W2157856480 @default.
• W4376598514 cites W2170326270 @default.
• W4376598514 cites W2175975424 @default.
• W4376598514 cites W2194258360 @default.
• W4376598514 cites W2747575897 @default.
• W4376598514 cites W2751649240 @default.
• W4376598514 cites W2775322784 @default.
• W4376598514 cites W2800655239 @default.
• W4376598514 cites W2801757328 @default.
• W4376598514 cites W2954450299 @default.
• W4376598514 cites W3042735001 @default.
• W4376598514 cites W3126311370 @default.
• W4376598514 cites W3187645783 @default.
• W4376598514 cites W4211073787 @default.
• W4376598514 cites W4224271819 @default.
• W4376598514 cites W4289711905 @default.
• W4376598514 doi "https://doi.org/10.1007/s40262-023-01254-2" @default.
• W4376598514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37179512" @default.
• W4376598514 hasPublicationYear "2023" @default.
• W4376598514 type Work @default.
• W4376598514 citedByCount "0" @default.
• W4376598514 crossrefType "journal-article" @default.
• W4376598514 hasAuthorship W4376598514A5017147502 @default.
• W4376598514 hasAuthorship W4376598514A5024637021 @default.
• W4376598514 hasAuthorship W4376598514A5062283881 @default.
• W4376598514 hasAuthorship W4376598514A5069728691 @default.
• W4376598514 hasAuthorship W4376598514A5075015951 @default.
• W4376598514 hasAuthorship W4376598514A5076058449 @default.
• W4376598514 hasBestOaLocation W43765985141 @default.
• W4376598514 hasConcept C112705442 @default.
• W4376598514 hasConcept C126322002 @default.
• W4376598514 hasConcept C16005928 @default.
• W4376598514 hasConcept C181389837 @default.
• W4376598514 hasConcept C2776239304 @default.
• W4376598514 hasConcept C2777071850 @default.
• W4376598514 hasConcept C2777288759 @default.
• W4376598514 hasConcept C2778566413 @default.
• W4376598514 hasConcept C2779548794 @default.
• W4376598514 hasConcept C2908647359 @default.
• W4376598514 hasConcept C44249647 @default.
• W4376598514 hasConcept C71924100 @default.
• W4376598514 hasConcept C98274493 @default.
• W4376598514 hasConcept C99454951 @default.
• W4376598514 hasConceptScore W4376598514C112705442 @default.
• W4376598514 hasConceptScore W4376598514C126322002 @default.
• W4376598514 hasConceptScore W4376598514C16005928 @default.
• W4376598514 hasConceptScore W4376598514C181389837 @default.
• W4376598514 hasConceptScore W4376598514C2776239304 @default.
• W4376598514 hasConceptScore W4376598514C2777071850 @default.
• W4376598514 hasConceptScore W4376598514C2777288759 @default.
• W4376598514 hasConceptScore W4376598514C2778566413 @default.
• W4376598514 hasConceptScore W4376598514C2779548794 @default.
• W4376598514 hasConceptScore W4376598514C2908647359 @default.
• W4376598514 hasConceptScore W4376598514C44249647 @default.
• W4376598514 hasConceptScore W4376598514C71924100 @default.
• W4376598514 hasConceptScore W4376598514C98274493 @default.
• W4376598514 hasConceptScore W4376598514C99454951 @default.
• W4376598514 hasFunder F4320337364 @default.
• W4376598514 hasIssue "7" @default.
• W4376598514 hasLocation W43765985141 @default.
• W4376598514 hasLocation W43765985142 @default.
• W4376598514 hasLocation W43765985143 @default.
• W4376598514 hasOpenAccess W4376598514 @default.
• W4376598514 hasPrimaryLocation W43765985141 @default.
• W4376598514 hasRelatedWork W1555144605 @default.

• next